Your browser doesn't support javascript.
The Post-Vaccination Quantitative Total Immunoglobulin Levels against SARS-CoV-2 in Healthcare Workers: A Multi-Centric Cohort Study in India.
Babu, Mangayarkarasi V; Debnath, Dhrubajyoti J; Tripathi, Mukesh; Samatha, Yalamanchili; Shankar, Sumita; Kattimani, Vivekanand; Manikam, Dhanasekar Voloya; Kumar, Pradeep.
  • Babu MV; All India Institute of Medical Sciences, Mangalagiri 522503, Andhra Pradesh, India.
  • Debnath DJ; All India Institute of Medical Sciences, Mangalagiri 522503, Andhra Pradesh, India.
  • Tripathi M; All India Institute of Medical Sciences, Mangalagiri 522503, Andhra Pradesh, India.
  • Samatha Y; SIBAR Institute of Dental Sciences, Guntur 522509, Andhra Pradesh, India.
  • Shankar S; Guntur Institute of Medical Sciences, Guntur 522004, Andhra Pradesh, India.
  • Kattimani V; SIBAR Institute of Dental Sciences, Guntur 522509, Andhra Pradesh, India.
  • Manikam DV; All India Institute of Medical Sciences, Mangalagiri 522503, Andhra Pradesh, India.
  • Kumar P; All India Institute of Medical Sciences, Mangalagiri 522503, Andhra Pradesh, India.
Vaccines (Basel) ; 10(9)2022 Sep 15.
Article in English | MEDLINE | ID: covidwho-2044011
ABSTRACT
Healthcare workers (HCWs) in India received the AZD1222 and BBV152 vaccines from January 2021 onwards. The objective of this study was to compare the immune response (seropositivity rate and geometric mean titer (GMT), and 95% confidence interval (CI)] against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in HCWs who received these vaccines, after the first and second doses. Therefore, the total immunoglobulin (Ig) levels specific to SARS-CoV-2 were measured using quantitative enzyme-linked immunosorbent assay (ELISA). The study population of 133 HCWs consisted of two groups in which the immune response was measured for the AZD1222 and BBV152 vaccines. Data collection was performed from 6 February to 20 August 2021. Four weeks after the first and second dose, the odds ratio of seroconversion for AZD1222 and BBV152 vaccine was 10.3 times (95% CI 4.5-23.7) and 15.9 times (95% CI 6.3-39.9), respectively. The GMT was 6392.93 and 6398.82 U/mL for AZD1222 and 1480.47 and 990.38 U/mL for BBV152 after the first and second doses, respectively. Both vaccines elicited an immune response, but the seroconversion rate and GMT after each dose were significantly higher for AZD1222 than those for the BBV152 vaccine in this study.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091535

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091535